Pages that link to "Q45059448"
Jump to navigation
Jump to search
The following pages link to A dose-finding and pharmacokinetic study of the matrix metalloproteinase inhibitor MMI270 (previously termed CGS27023A) with 5-FU and folinic acid (Q45059448):
Displaying 6 items.
- Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease (Q25256594) (← links)
- Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. (Q37756119) (← links)
- Matrix metalloproteinase-2 as a target for head and neck cancer therapy (Q38068476) (← links)
- Is there new hope for therapeutic matrix metalloproteinase inhibition? (Q38265674) (← links)
- Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment (Q38725320) (← links)
- Caffeoyl pyrrolidine derivative LY52 inhibits hepatocellular carcinoma invasion via suppressing matrix metalloproteinase-2 (Q42089632) (← links)